2026 Future Healthcare and Medicine Conference · Panlin Capital Post-investment Empowerment Seminar centers on reassessing high-quality assets within China’s innovative medical sector. At the 2026 AACR Annual Meeting, 104 Chinese pharmaceutical enterprises showcased over 250 research achievements, breaking the dominance of multinational industry giants. In 2025, China granted approval to 76 innovative drugs and 76 innovative medical devices. As of 2026, the total value of BD transactions involving domestic innovative drugs has surpassed $49 billion. China’s medical innovation industry is evolving from a fast follower into a systematic innovator. Multinational corporations have fundamentally adjusted their evaluation criteria for Chinese medical innovative assets and shifted focus to strategic industrial layout. Li Yuhui, Founding Managing Partner of Panlin Capital, stated that revaluing premium innovative medical assets in China has become a core industry topic.

DVT most commonly occurs in the lower extremities, and its major adverse consequences are pulmonary thromboembolism (PE) and post-thrombotic syndrome (PTS). Acute PE has a mortality rate as high as 20%–30%, representing an extremely high risk of fatality. If acute DVT is not diagnosed and treated in a timely manner, it can progress to chronic DVT, with 30%–50% of patients developing PTS within two years。

20n Bio's platform enables rapid discovery of high-affinity, high-selectivity cyclic peptide binders against a wide range of disease-related targets from ultra-large cyclic peptide libraries. The Company has demonstrated de novo cyclic peptide discovery capabilities across multiple targets; several molecules discovered through the platform have generated in vivo data through out-licensed programs, further supporting the translational potential of the platform's discovered molecules.

Forlong Biotechnology has established a globally leading integrated synthetic immunology technology system, comprising four proprietary core technology platforms: the Fbody® long-acting platform, the Syntokine® novel synthetic cytokine platform, the Fc engineering platform, and the AI-powered macromolecule intelligent discovery platform. These four platforms enable multi-dimensional optimization of protein therapeutics, particularly cytokines, with the goal of overcoming the developability challenges of cytokines and developing novel biologics with high safety profiles and excellent efficacy.

At the recently held 2026 Future Healthcare and Medicine Conference in Shanghai, leading executives and investors from China and the global healthcare industry gathered to discuss the future of medical and pharmaceutical innovation. The agenda covered not only technology-driven trends such as AI-enabled innovation and end-to-end digitalization, but also a critical challenge facing Chinese healthcare companies as they expand globally: how to move beyond “product expansion” and achieve “true brand expansion”.

By the end of 2026, Full-Life expects to have three differentiated clinical-stage programs, all originating from its proprietary UniRDC™ discovery platform. In addition, the funds will support the initiation of GMP-grade actinium-225 (225Ac) isotope production at the Company's advanced manufacturing facility in Belgium. The ability to control isotope supply and production in-house represents a key strategic advantage for Full-Life as it accelerates clinical development of its radiotherapeutics.

Bivision Pharmaceuticals has completed nearly 400 million RMB Series B financing. The round was co-led by Pudong Innovation Investment, ZJ Venture Investment, and IDG Capital, with participation from existing shareholder Gaorong Ventures ( increased investment ) and Saleland Innovation, among others. No financial advisor was disclosed. Proceeds from this round will be allocated to confirmatory clinical studies for core pipeline programs, technology platform iteration, advancement of differentiated innovative pipelines, and planning for a radiopharmaceutical R&D center. The company's core pipeline asset JH02 is expected to achieve domestic substitution and is undergoing Phase I clinical studies across multiple tumor types. Other pipeline programs are in active R&D and clinical translation. Dr. Haihua Yu, Founder of Bivision Pharmaceuticals, stated that the financing will empower the company's core pipeline to compete globally and benefit cancer patients worldwide.

Brainsmart Technology announced the completion of its angel round series financing totaling over $10 million. The round was led sequentially by Bayland Capital and Lanchi Ventures, with Fosun Health Capital participating as an investor. Proceeds from this financing will be primarily used for product engineering, the development of neural foundation models, and the construction of GMP production facilities. The funding aims to accelerate overcoming the challenges of stable application of brain-computer interfaces (BCI) in real-world scenarios. Founded by Professor Paddy Chan of the University of Hong Kong and incubated under the InnoHK-ABIC platform of the Hong Kong Innovation and Technology Commission, Brainsmart Technology possesses world-class research capabilities, a global intellectual property portfolio, and extensive clinical translation experience.

Fundable early-stage medical AI projects are gradually shrinking, while only mid-to-late stage players continue to secure financing. Medical AI faces inherent hidden entry barriers. The director of the pathology department at a top tertiary hospital in Chengdu partnered with Cheng An to digitize colorectal cancer diagnostic expertise into a systematic platform. Leveraging experience in internet AI, Cheng An’s team rolled out the first version of the model within half a year. Yet during further optimization, they found it difficult to access external clinical data beyond their partner hospital. The team later adopted new algorithms to boost detection accuracy. Nevertheless, the barriers to the healthcare industry far exceeded Cheng An’s expectations. Medical AI lacks clear payers, making it hard for initial products to achieve rapid monetization, leaving the team in urgent need of external capital to sustain operations.

On May 13, 2026, Kelun-Biotech’s tetravalent bispecific antibody SKB118 targeting PD-1 and VEGF was approved for clinical trials in China to treat advanced solid tumors. Statistically, SKB118 is the world’s 19th PD-1/PD-L1 × VEGF bispecific antibody that has entered clinical or later-stage development. So far, only one candidate from Akeso Biopharma has been approved for marketing, resulting in fierce market competition. SKB118 boasts differentiation beyond its dual-target design. Preclinical studies show its self-enhancing activity is a structural advantage derived from its tetravalent format. More importantly, Kelun-Biotech’s true competitive edge lies in the synergy between SKB118 and its proprietary ADC pipeline, as the company seeks to unlock the therapeutic potential of the bispecific antibody + ADC combination strategy.